My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1925

    1.

    Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.

    Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ.

    Diabetes. 2008 Mar;57(3):678-87. Epub 2007 Dec 5.PMID: 18057091 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

    Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.

    J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13.PMID: 12788877 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.

    Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B.

    Diabetes. 2004 Mar;53(3):654-62.PMID: 14988249 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.

    Greenfield JR, Farooqi IS, Keogh JM, Henning E, Habib AM, Blackwood A, Reimann F, Holst JJ, Gribble FM.

    Am J Clin Nutr. 2009 Jan;89(1):106-13. Epub 2008 Dec 3.PMID: 19056578 [PubMed - indexed for MEDLINE]Related articles

    5.

    Incretin and islet hormonal responses to fat and protein ingestion in healthy men.

    Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, Deacon CF, Ahrén B.

    Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E779-84. Epub 2008 Jul 8.PMID: 18612044 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.

    Vaag AA, Holst JJ, Vølund A, Beck-Nielsen HB.

    Eur J Endocrinol. 1996 Oct;135(4):425-32.PMID: 8921824 [PubMed - indexed for MEDLINE]Related articles

    7.

    Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.

    Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, Deacon CF, Gallwitz B, Schmidt WE, Meier JJ.

    Regul Pept. 2004 Nov 15;122(3):209-17.PMID: 15491793 [PubMed - indexed for MEDLINE]Related articles

    8.

    Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

    Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.

    J Clin Invest. 1993 Jan;91(1):301-7.PMID: 8423228 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

    Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ.

    Diabetes. 2001 Mar;50(3):609-13.PMID: 11246881 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.

    Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ.

    J Clin Endocrinol Metab. 2001 Aug;86(8):3717-23.PMID: 11502801 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance.

    Ahrén B, Larsson H, Holst JJ.

    Eur J Endocrinol. 1997 Aug;137(2):127-31.PMID: 9272099 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus.

    Cypryk K, Vilsbøll T, Nadel I, Smyczyńska J, Holst JJ, Lewiński A.

    Gynecol Endocrinol. 2007 Jan;23(1):58-62.PMID: 17484514 [PubMed - indexed for MEDLINE]Related articles

    13.

    Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance.

    Rask E, Olsson T, Söderberg S, Holst Jj J, Tura A, Pacini G, Ahrén B.

    Metabolism. 2004 May;53(5):624-31.PMID: 15131768 [PubMed - indexed for MEDLINE]Related articles

    14.

    Ethanol with a mixed meal decreases the incretin levels early postprandially and increases postprandial lipemia in type 2 diabetic patients.

    Dalgaard M, Thomsen C, Rasmussen BM, Holst JJ, Hermansen K.

    Metabolism. 2004 Jan;53(1):77-83.PMID: 14681846 [PubMed - indexed for MEDLINE]Related articles

    15.

    Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

    Regul Pept. 2003 Jul 15;114(2-3):115-21.PMID: 12832099 [PubMed - indexed for MEDLINE]Related articles

    16.

    Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.

    Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Egan JM.

    Am J Physiol Endocrinol Metab. 2006 Mar;290(3):E550-9. Epub 2005 Oct 11.PMID: 16219666 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy.

    Fukase N, Manaka H, Sugiyama K, Takahashi H, Igarashi M, Daimon M, Yamatani K, Tominaga M, Sasaki H.

    Acta Diabetol. 1995 Oct;32(3):165-9.PMID: 8590785 [PubMed - indexed for MEDLINE]Related articles

    18.

    alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.

    Hücking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, Nauck MA.

    Diabet Med. 2005 Apr;22(4):470-6.PMID: 15787675 [PubMed - indexed for MEDLINE]Related articles

    19.

    The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.

    Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.

    Diabetes Obes Metab. 2002 Sep;4(5):329-35.PMID: 12190996 [PubMed - indexed for MEDLINE]Related articles

    20.

    Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.

    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.

    J Clin Endocrinol Metab. 1993 Apr;76(4):912-7.PMID: 8473405 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity